Symposium
Cannabis Health Symposium: London
The UK is forecasted to have up to 130k patients this year. London will feature evidence-based education for UK clinicians, prescribers and the wider medical cannabis community.
Healthcare professional?

- Date
- 26 November 2026
- Time
- 08:30 – 17:00
- Location
- Conway Hall, London, United Kingdom
- Who it’s for
- Healthcare professionals & clinicians · Industry professionals · Patient advocates
- CPD
CPD certified — Accredited by The CPD Certification Service- Included
- 12 months' free MCCS membership — worth up to £120
Final Release£284.09incl. fees
HCP concession£100for healthcare professionals
Every ticket: CPD certified · 12 months' free MCCS membership, worth up to £120
The Cannabis Health Symposium returns to London for a full day of evidence-led education across policy, regulation, access and clinical practice — bringing together healthcare professionals, industry and patient advocates.
Programme
26 November 2026 · 08:30 – 17:00 · 22 sessions, including 4 panel debates
Programme subject to change — session times, titles and speakers may be updated.
- 08:30Doors open — registration & networking coffee
- 09:20
Opening remarks & welcome
Sarah Sinclair · Editor, Cannabis Health
- 09:30
Presentation
Curaleaf Education Platform: Free Education for Prescribers
The Symposium's headline partner, Curaleaf, introduces its education platform: free education for prescribers.
Morning session: Policy, regulation & access
- 10:00
Fireside chat
Making the UK a Cannabinoid Science Leader: A Fireside with Professor Trevor Jones
Trevor Jones · Co-Chair, UK Cannabinoid R&D Group
Sarah Sinclair · Editor, Cannabis Health
Eight years after cannabis-based medicines were rescheduled in the UK, the research base has barely moved. Only three cannabis-based medicines have been approved for prescription, and the vast majority of products prescribed are unlicensed, supplied via the specials route and administered by private clinics. Prescribers are asked to make decisions without the trial data they would expect for any other therapeutic class, while the researchers who could generate that data face a regulatory framework that still treats most of the plant's compounds as having no medicinal value. The result is a field where clinical demand has run far ahead of the evidence, and where the UK risks ceding scientific leadership to countries that have made research easier.
Read more
Professor Trevor Jones has spent a career at the intersection of pharmaceutical R&D and national policy, and as co-chair of the Cannabinoid Research and Development Group alongside George Freeman MP, he is leading the effort to change that picture. The group set out to produce the country's first comprehensive strategy for cannabinoid R&D, integrating universities, research institutions, investors, businesses and the NHS. In this conversation he sets out the CRDG's priorities, from reform of Schedule 1 licensing and clearer MHRA guidance to the case for targeted research exemptions, and explains what a functioning pathway from lab to licensed medicine would actually require. For the prescribers and policymakers in the room, it is a rare chance to hear the argument directly from the person making it to government.
This fireside discusses why Schedule 1 remains the single biggest barrier to UK cannabinoid research, what practical changes to Home Office licensing and MHRA guidance would unlock trials fastest, how research exemptions could work without weakening controls, and what role clinicians can play in building the evidence base the field needs.
- 10:20
Panel discussion
Building a safe, effective and compliant medical cannabis service
David Tang · CEO & Founder, CannPrescribe
Adam Cole · Chief Technology & Program Strategist, Goji Technology Systems Inc
Nitin Makadia · Director of Clinical Service Development, The Digital Health Assurance Company
As the sector continues to mature, robust governance and regulatory compliance remain essential for clinics providing cannabis-based medicines. This practical panel will explore the systems, processes and quality standards required to meet Care Quality Commission expectations, and how the same process works in other key markets outside the UK.
Read more
Attendees will gain insight into common challenges, lessons learned from inspections, and practical strategies for achieving and maintaining good or outstanding ratings. The session is designed for clinic operators, medical directors and governance leads seeking to strengthen their compliance frameworks and improve patient safety.
- 11:00
Presentation
Medical cannabis in the workplace: safety, compliance and employee rights
Professor Kim Wolff · Director of King's Forensics, King's College London
As the number of prescribed medical cannabis patients continues to grow, employers and occupational health professionals are increasingly faced with complex questions around workplace safety, drug testing, fitness for work and reasonable adjustments. This session will explore the legal and practical considerations surrounding medical cannabis in employment settings, including the challenges faced by patients working in safety-critical roles — towards fair, evidence-based workplace policies.
- 11:30
Presentation
Medical cannabis police guidance: understanding rights and responsibilities
Richard List QPM · National Secretary and CDLO, Association of Police Controlled Drug Liaison Officers
Despite legalisation, many medical cannabis patients continue to experience confusion and inconsistency when interacting with law enforcement. This session will present the latest police guidance for medical cannabis patients, helping clinicians, patients and healthcare providers better understand the practical implications of the law and how it is being applied across the UK.
- 12:00
Presentation
Setting the Standard: How Harmonisation Turns CBMs Into Trusted Care
Ana Serrato · Chair, Cannabis Human Health Subcommittee (D37.11); Chairwoman, EUMCA, ASTM International
Across Europe, early access programmes for cannabis-based medicines run under fragmented, country-specific rules, each with its own quality expectations, evidence requirements and pathway to patients. That fragmentation leaves manufacturers, regulators and healthcare professionals without a shared language, making it hard to guarantee that patients receive consistently high-quality, safe products wherever they are treated.
Read more
That is the gap ASTM D37.11: Human Health is built to close, covering product quality, health evidence and responsible use in one framework. Closing it gives manufacturers one consistent technical reference, healthcare professionals reliable evidence to guide prescribing, patients assurance of quality and safety, regulators a harmonised benchmark, and investors the predictability needed for cross-border trade. Trusted cannabinoid-based care will not come from national regulation alone. It requires one shared standard, built for the full journey from product to patient.
- 12:20
Presentation
Headline partner presentation — Curaleaf Laboratories
- 12:40
Presentation
Real-world use of cannabinoid-based medicines in routine clinical practice: treatment patterns and physician-reported outcomes
Dr Julian Haist · Medical Affairs Representative, Tilray Medical
Cannabinoid-based medicines are increasingly being used in patients with complex and often chronic conditions. Drawing on 106 documented cases from the Physicians Experience Platform (PEP), this analysis examines treatment patterns, dosing, tolerability and physician-reported outcomes in routine clinical practice. The findings offer practical real-world insights into the management of patients who have frequently received extensive prior treatments.
- 13:00Lunch & networking
Afternoon session: Science and clinical practice
- 14:00
Panel discussion
Managing risk and maximising benefit in mental health care
Edward Chesney · Clinical Lecturer, King's College London
Dr Iain Pryde · Consultant Psychiatrist, Tilray Medical x Lyphe Clinic
Kate Thorpe · Executive Director, Medical Cannabis Clinicians Society (MCCS)
Mental health remains one of the most discussed and debated areas of medical cannabis practice. This session will examine the current evidence for cannabis-based medicines in psychiatric conditions, while addressing concerns around safety, dependency, psychosis risk and patient selection. Leading psychiatrists and clinicians will discuss prescribing considerations, risk mitigation strategies and the role of cannabis-based medicines within wider mental health treatment pathways. The session will provide practical guidance for clinicians navigating this complex and evolving area of practice.
- 14:40
Presentation
Cannabis for Neurological Disorders and Neurodiversity: Fact or Fiction?
Interest in the use of cannabis-based medicines for neurodevelopmental conditions continues to grow among clinicians, patients and families. This panel discussion will examine the current evidence surrounding the use of CBMPs in Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, while exploring gaps in conventional treatment options and emerging understanding of the endocannabinoid system in neurodivergent populations. Combining clinical expertise, research perspectives and lived experience, the session will provide a balanced discussion of the opportunities, challenges and unanswered questions in this rapidly evolving area.
- 15:00
Presentation
RCT vs RWE: is it time to look beyond the placebo-controlled trial?
Professor David Nutt · Professor of Neuropsychopharmacology, Imperial College London, Drug Science
For the last 50 years, randomised controlled trials (RCTs) have been considered the 'gold standard' in research measuring the safety and efficacy of new drugs. But there are known limitations of these types of studies, particularly in cannabinoid medicine, and some argue we should give greater weight to other types of evidence like real-world data when determining whether treatments are safe and effective. This session will explore whether it's time for the scientific community to look beyond the double-blind placebo-controlled trial.
- 15:30
Presentation
Addressing unmet needs in women's health
Dr Grace Blest-Hopley · Founder & Researcher, Hystelica
Women are increasingly seeking cannabis-based medicines to manage a range of conditions that are often poorly served by conventional treatment options. This session will explore the use of medical cannabis across menopause, endometriosis, PMDD, chronic pelvic pain and related disorders — examining the current evidence, clinical experience and future research priorities, and how healthcare providers can better support women seeking alternative treatment approaches.
- 15:50
Panel discussion
Medical Cannabis and Pain Treatment: What Real World Evidence Tells Us
Dr Simon Tordoff · Consultant in Pain Management, CB1 Medical
Garvin Hirt · Co-Founder & CEO, Copeia
Nabila Chaudhri · Medical Director, Montu UK / Alternaleaf
Dr Zack Bellman · Lead Researcher, CRDG UK; Founder, Cannabinoid Pipeline Insights
Chronic pain remains the most common reason patients seek a medical cannabis prescription, yet the evidence base is still catching up with clinical demand. This panel brings together registry data, prescribing experience and independent clinical scrutiny to ask what the real-world evidence actually shows, and where it falls short.
Read more
Drawing on UK Medical Cannabis Registry outcomes, frontline prescribing experience and the perspective of the Advisory Council on the Misuse of Drugs, speakers will examine THC:CBD response patterns, opioid-sparing potential, and the data gaps still standing between promising patient outcomes and broader clinical or reimbursement acceptance. Rather than another advocacy panel, this session is built to stress-test the evidence itself: what counts as robust data, what remains anecdotal, and what needs to happen next for medical cannabis to earn its place in mainstream pain management.
- 16:20
Panel discussion
Patient Voices: Real-World Experiences of Prescribed Cannabis-Based Medicines
Julie Durrans · Prescribed patient & patient advocate
Carola Pérez · Director, We, The Patients
Nicola Stevenson · Prescribed patient, advocate & industry consultant, The M-C Fairy
Liam O'Dowd · Editor & Co-Founder, leafie
Cannabis is a very personalised treatment and good communication between prescribers and their patients is crucial. Listening to the patients' perspective provides clinicians with a vital source of insight into the real-world impact of these medicines, which can help inform future prescribing decisions.
Read more
This patient panel will give healthcare and industry professionals a unique opportunity to hear directly from patients about their lived experiences with cannabis-based medicines, from navigating access to managing day-to-day treatment. It will explore how prescribers and the wider care team can work effectively with patients to build trust, meet their needs and deliver person-centred care.
- 17:00Close
- 17:00Post-conference drinks — The Enterprise, 38 Red Lion Street, Holborn (until 19:00)
Workshop stage — runs alongside the main programme
- 10:00
Roundtable
Patients Roundtable: Medical Cannabis Patient Voices
This roundtable brings together patient-led organisations — We, The Patients, Patients First UK, PatientsCann UK and United Patients Alliance — who speak for people across the UK and Europe who use or are seeking medical cannabis, including many living with chronic pain, neurological conditions and other long-term illness.
Read more
It is a collaborative, patient-led discussion in which the organisations share what their members tell them about access and affordability, product quality and consistency, rights in daily life such as work, travel and driving, stigma, and the quality of information available to patients. Industry representatives are invited to listen in rather than present or pitch, so that manufacturers, prescribers, pharmacies and others gain a first-hand view of what patients need and can respond to it in their own work.
- 10:50
Interactive workshop
Patient Discrimination: Understanding Rights, Managing Incidents and Supporting Patients
Alex Fraser · Founder & Managing Director, Patient Protect
An interactive training workshop for medical cannabis prescribers and healthcare professionals. While medical cannabis has been legally prescribed in the UK since 2018, patients continue to encounter stigma, misunderstanding and discrimination in their everyday lives. Led by Alex Fraser, founder of Patient Protect, this workshop will equip prescribers with the knowledge and confidence to better support patients facing challenges relating to their prescribed medication.
Read more
Drawing on real-world cases reported to Patient Protect, the session will explore common areas of discrimination, including policing and driving, employment, housing and child custody. Participants will examine relevant legal protections, how incidents typically unfold, and the practical steps clinicians and clinics can take to support affected patients. Using case studies, patient reporting data and interactive discussion, it will explore how healthcare professionals can help prevent misunderstandings, respond effectively when problems arise, and empower patients to exercise their rights with confidence.
The session will also consider the wider role of prescribers and the medical cannabis industry in tackling stigma, improving public understanding and promoting the normalisation of prescribed cannabis medicines, and concludes with an introduction to Patient Protect's support services and resources for patients and prescribing clinics.
- 11:20
Presentation
Nurses in Cannabis Care: The Case for Expanding Nursing Roles in the UK Sector
Adam Windish · CEO, British Cannabis; Education, Awareness & Standards Pillar Lead, Cannabis Industry Council
The UK medical cannabis sector has expanded rapidly since cannabis-based products for medicinal use (CBPMs) were legalised in 2018, yet nursing involvement remains underdeveloped. The sector is largely private and telemedicine-led, while the pool of specialist prescribers who can initiate unlicensed CBPM treatment remains limited.
Read more
Adam Windish, Awareness, Standards & Education Pillar Lead for the Cannabis Industry Council, presents the CIC's newest educational report, produced in partnership with Ariana Ayu, RN, MSc, founder of the CannyNurse Certificate Program. "Nurses in Cannabis Care" argues for a structured expansion of nursing roles, supported by specialist education, clear governance and defined escalation pathways.
- 11:50
Presentation
Patient Safety and the Illicit Market: What Prescribers Need to Know
Shanna Marrinan · Director of Research, 4C Labs
Medical cannabis has an unusually strong safety profile, and even in illicit markets, serious harm is rare. But rare is not the same as absent, and where risk does show up, it rarely comes from the cannabis itself. This session presents new analysis of UK drug-checking data from WEDINOS (Welsh Emerging Drugs & Identification of Novel Substances), examining 578 cannabis-intent samples submitted over an 18-month period through anonymous postal testing and police and prison seizures. Using LC-QTOF chemical analysis capable of detecting novel psychoactive substances, the research found that nearly half of all samples (48.79%) were compromised: containing substances with no natural place in cannabis. Most strikingly, 188 samples contained no cannabinoids at all, having been fully substituted with an active adulterant, while a further 37 combined cannabis with an added psychoactive compound.
Read more
The scale of synthetic cannabinoid receptor agonist contamination is a key finding, present in over a quarter of all samples tested, with MDMB-4en-PINACA alone detected in one in five. For clinicians and policymakers, this raises a pointed question: how much of the harm attributed to "cannabis" in unregulated settings is actually harm from something else entirely, deliberately added to boost perceived potency or appeal. The session will walk through the data, unpack the likely motivations and consequences behind this kind of adulteration, and consider what it means for the case for a fully regulated, GMP-certified medical cannabis supply chain, where this category of risk is largely designed out.
This session covers: how common is adulteration really, what compounds are showing up and why, what these findings suggest about supply chain risk versus cannabis risk itself, and how regulation and GMP standards change the picture.
- 12:20
Workshop
Prescription to Pharmacy: Inside Greece's Medical Cannabis Framework
Panos Papatheologou · Co-Founder & CEO, ReliefTime
Greece was one of Europe's earliest movers on medical cannabis, legalising it in 2017, yet patients waited almost seven years for the first legal prescriptions to be filled. What emerged is one of the continent's most tightly defined models. Every product must be authorised as a finished pharmaceutical by the national regulator, prescriptions flow through the country's national e-prescribing system and can be filled at any pharmacy, and patients pay the full cost with no reimbursement. A new generation of telemedicine services connecting patients with Greek-licensed doctors by video has entered that structure.
Read more
In this session, we'll learn how that infrastructure works day to day, from eligibility and consultation through to the pharmacy counter. This workshop explores how Greece's pharmaceutical-grade product requirements shape patient access, how national e-prescribing compares with the UK's private clinic and pharmacy pathway, what telemedicine looks like under each framework, and which elements of the Greek model could realistically translate to the UK.
- 14:30
Presentation
The Economics of Cannabis Patient Self-Sufficiency: A Global Perspective
Dr Callie Seaman · Managing Director, Sunnyside Consultants
As cannabis legislation continues to evolve worldwide, countries have adopted a range of regulatory approaches, from strictly controlled medical access to adult-use legalisation. Several jurisdictions have also introduced provisions for patients to cultivate their own cannabis or access it through designated growers, offering alternative models of patient self-sufficiency.
Read more
This session will explore these international approaches and examine the broader economic implications of patient self-sufficiency. Moving beyond the direct financial benefits to patients, Dr Callie Seaman will consider the potential impacts on healthcare expenditure, public finances, law enforcement, local communities and the wider economy.
Drawing on international examples and emerging UK research, the presentation will explore the opportunities, challenges and regulatory considerations associated with patient cultivation and designated growing models, opening a balanced, evidence-led discussion about their potential relevance to future UK cannabis policy.
Included: 12 months' free MCCS membership — worth up to £120
Secure your place — checkout is handled securely via Eventbrite.
Speakers

Professor David Nutt
Professor of Neuropsychopharmacology, Imperial College London, Drug Science
Read bio
David is Prof of Neuropsychopharmacology at Imperial College London and CRO Awaknlifesciences. He trained at Cambridge and Guy’s hospital to MRCP then did his psychiatry training and DM at the MRC Clinical Pharmacology Unit Oxford after which he became a Wellcome Senior Fellow. He then spent two years as heading the research ward at NIAAA in Washington DC before setting up the Psychopharmacology unit at Bristol University in 1988, where he later became Prof of Psychiatry and Dean of Clinical Medicine before moving to Imperial in 2008. He has held presidencies of the EBC, BAP, BNA and ECNP, was chair of the ACMD and founded the charity DrugScience. He has over 500 original research papers, a similar number of reviews/book chapters, eight government reports and 36 books. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science and in 2017 a Doctor of Laws hon causa from the University of Bath

Alex Fraser
Founder & Managing Director, Patient Protect
Prescription cannabis patients continue to face discrimination in policing, employment, healthcare and everyday life, often because the law and patients’ rights are poorly understood. Through Patient Protect, I see the real-world consequences of that misunderstanding regularly. I’m looking forward to bringing those experiences to the Cannabis Health Symposium, exploring where discrimination occurs, why it happens, and what patients, professionals and organisations can practically do about it.
Read bio
Alex Fraser is a UK medical cannabis patient advocate and industry professional with over a decade of experience supporting patients and improving understanding of prescription cannabis.
He co-founded the United Patients Alliance in 2014, campaigning for legal access to cannabis medicines through to the UK law change in 2018.
In 2025 Alex founded Patient Protect, an organisation supporting prescription cannabis patients experiencing discrimination and legal difficulties. Through this work, he has supported patients facing issues involving policing, employment, housing, healthcare, driving and access to services, and works to improve understanding of patients’ rights among organisations and public authorities.
He is ABPI qualified, regularly speaks at cannabis, healthcare and policing conferences, and brings both professional and lived experience as a long-term prescribed cannabis patient for his Crohn’s Disease.

Richard List QPM
National Secretary and CDLO, Association of Police Controlled Drug Liaison Officers
My priority is to increase knowledge and understanding about medical cannabis amongst police officers and police staff. And to create consensus, cooperation and collaboration with patients, health care partners, the medical cannabis industry and wider community.
Read bio
Richard List is the National Secretary of the Association of Police Controlled Drug Liaison Officers. He retired after thirty years as a Detective Chief Superintendent, and for many years led the Thames Valley Police Drug Squad. He was a Police Gold Commander and has extensive policing experience. He is the author of the Official UK Police Guidance on Medical Cannabis — “Patient First, Suspect Second” (2025), and is currently working on a second edition. He is the Police Representative on the national CQC Drugs Group, and was awarded a Queen’s Police Medal (QPM) in 2001.

Shanna Marrinan
Director of Research, 4C Labs
I am honoured to participate in an event aimed specifically at the education of health professionals around medical cannabis. My professional drive is centred on building evidence-led, clinically-grounded research, in the hope of supporting development of good policy and clinical practice in this growing sector of medicine. The Cannabis Health Symposium embodies this same focus, and I’m very proud to be a part of that.
Read bio
Dr. Shanna Marrinan is Research Director at 4C Labs, and was formerly Chair of the Cannabis Industry Council Research Committee, and member of the Drug Science Medical Cannabis Working Group. Shanna also continues to work as an Independent Consultant, formerly at London School of Hygiene and Tropical Medicine, the Houses of Parliament, and University College London, and lectures one day a week at IES. She was previously a research fellow at the Novel Psychoactive Substances Unit, University of Hertfordshire, and has published internationally on issues of drugs policy, toxicology and pharmacology. Her principal research interest focuses on the therapeutic applications for medical cannabis.

Professor Kim Wolff
Director of King's Forensics, King's College London
Looking forward to knowledge sharing and lively debate
Read bio
Professor Kim Wolff is Director of King’s Forensics at King’s College London and Head of the Drug Control Centre, the UK’s only WADA-accredited anti-doping laboratory. She also leads King’s Forensics Mass Spectrometry Services (KF-MSS), which provides specialist cannabis and cannabinoid testing services using advanced liquid chromatography–mass spectrometry (LC-MS) techniques.
An internationally recognised expert in analytical toxicology, Professor Wolff specialises in the detection and interpretation of drugs, metabolites, cannabinoids, and other biomarkers in a range of biological matrices. Her work supports clinical trials, regulatory submissions, forensic investigations, and anti-doping programmes. She has advised national and international organisations on drug testing, cannabinoid safety, and analytical standards.
Professor Wolff received an MBE in 2016 for her contribution to UK drug-driving legislation. She continues to lead research into drug detection and metabolism, while overseeing testing programmes for major sporting events and developing innovative approaches to the identification of prohibited and emerging substances.

Ana Serrato
Chair, Cannabis Human Health Subcommittee (D37.11); Chairwoman, EUMCA, ASTM International
Read bio
Ana Serrato is a seasoned pharmaceutical executive with extensive expertise in innovative therapies, orphan drugs and, more recently, cannabinoid-based medicines (CBMs). With over 20 years of experience in the pharmaceutical and biotechnology sectors, she has held leadership roles at national and regional level in major pharmaceutical companies and biotech start-ups. Originally from Colombia, Ana relocated to Germany in 2019 as Global Pharma Head at Clever Leaves, and later joined Avextra Pharma, where she leads the Clinical Development Team. A passionate advocate for CBM research and data-driven, patient-centric policy, she was appointed Chairwoman of the European Medical Cannabis Association (EUMCA) in 2024 and recently Chair of ASTM's Cannabis Human Health Subcommittee. Ana holds a degree in Microbiology from the Universidad de los Andes, Bogotá, and an MBA from Universidad Carlos III, Madrid.

Dr Anna Waldstein
Senior Lecturer in Medical Anthropology, University of Kent
What roles do social, cultural and behavioural factors play in shaping medical cannabis outcomes? I look forward to discussing how social science concepts can be applied to improve patient care.
Read bio
Dr Anna Waldstein is a medical anthropologist and ethnobotanist at the University of Kent, one of the original co-founders of Breaking Convention: A Multidisciplinary Conference on Psychedelic Consciousness, and founder of Tree of Life Advisory Service (offering social science education and advice for medical cannabis providers). She has conducted ethnographic research with several Rastafari organisations in London on the importance of cannabis and other herbal medicines in the African Caribbean diaspora. Dr Waldstein has contributed to reports on cannabis-based medicines for the Conservative Drug Policy Reform Group and her research publications have been cited in the promotion of cannabis reform in the UK and Jamaica. In addition to traditional undergraduate and postgraduate teaching, she has also led training workshops on medical anthropology concepts, and on cultures of cannabis use to healthcare professionals.

Dr Simon Tordoff
Consultant in Pain Management, CB1 Medical
I must confess that I spent a large part of my career ignorant about the benefits of medical cannabis and I had no experience of prescribing it. I have learned so much in the last 4 years and it has been a stimulating and rewarding journey, and I have seen it help so many patients. I want to share with you what I've learned on this journey in the hope that it encourages more doctors to start prescribing cannabis in the future.
Read bio
Dr Simon Tordoff graduated in 1980 from the University of Cape Town Medical School in South Africa. He moved to the UK in 1987 and then specialised in Anaesthesia and Pain Management in London and Leicester.
He has worked in Pain Management for the past 35 years treating both chronic and cancer-related pain conditions. He has been prescribing medical cannabis products for the past 4 years.
He was involved in the establishment of the CB1 Medical clinic. This developed from a General Practice in Leicester and was launched in 2023. The clinic provides medical cannabis treatments for a wide range of clinical conditions.

Garvin Hirt
Co-Founder & CEO, Copeia
Read bio
Garvin Hirt is the Co-Founder and CEO of Copeia. Copeia is a German technology innovator that develops AI- and data-based solutions to optimise cannabis-based healthcare. Copeia supports both patients and the healthcare industry to drive improvements in personalised treatment. Copeia is helping everyone reimagine an approach that is smarter and more interconnected to evolve personal health. Garvin has a communication design and software development background and lives in Berlin.

Trevor Jones
Co-Chair, UK Cannabinoid R&D Group
Cannabinoid R&D is at an important crossroads in terms of government support and public and private investment. We need to work together to optimise the opportunity for future growth.
Read bio
Trevor Jones is Co-Chair of the UK Cannabinoid R&D Group. He is a former Global R&D Director of The Wellcome Foundation, a former Director General of the ABPI and a former Director of Allergan Inc (California). He is a former member of the UK regulatory agency the Medicines Commission.
He is currently a Director of TechImmune Inc, Tangram Therapeutics plc and EDX Medical Group plc.

Dr Grace Blest-Hopley
Founder & Researcher, Hystelica
Women are already turning to cannabis to manage unmet health needs, from menstrual pain to menopause, and the community evidence is clear. Yet we still don't understand how the menstrual cycle and female physiology interact with cannabis. Women deserve proper research and products designed for their health and wellbeing, not guesswork. I'm excited to be part of an event putting that gap front and centre.
Read bio
Dr Grace Blest-Hopley is a neuroscientist whose career spans more than a decade of cannabis and psychedelic research, from observational field studies to clinical drug development. She is a Research Associate at King's College London's Institute of Psychiatry, Psychology & Neuroscience, and an advisor to NWPharmaTech, a clinical-stage company developing a pharmaceutical-grade CBD medicine.
Grace is the founder of Hystelica, a research and education organisation tackling the gender gap in psychedelic medicine by putting female biology and women's health at the centre of the science. Her work explores how hormones, the menstrual cycle and sex differences shape responses to cannabinoids and psychedelics.
She is also Research Director at the Heroic Hearts Project, which supports veterans' mental health research.

Dr Julian Haist
Medical Affairs Representative, Tilray Medical
Real-world evidence complements clinical research and provides valuable insights into the use of cannabinoid-based medicines in everyday clinical practice.
Read bio
Julian Haist is a Medical Affairs Manager with a Ph.D. in Biology (Dr. rer. nat.) and is responsible for Medical Affairs activities in the German market, working closely with international teams. His expertise lies in the communication of scientific and regulatory information and in providing medical support to both internal and external stakeholders. His responsibilities include the development and review of medical content, the delivery of training programs, collaboration with healthcare professionals and scientific societies, and support for clinical and real-world evidence projects. Through the analysis and interpretation of scientific data, he derives actionable insights and contributes to the strategic advancement of medical initiatives.

Edward Chesney
Clinical Lecturer, King's College London
Read bio
Edward Chesney is a clinical lecturer at King’s College London and an honorary consultant psychiatrist at the Maudsley Hospital. He is an investigator on three clinical trials of cannabidiol (CBD) for people with early psychotic disorders and has conducted several experimental studies of the acute effects of CBD and THC in people with schizophrenia, people with cannabis dependence, and healthy volunteers. He has also researched the impact of cannabis withdrawal syndrome in psychiatric populations and the safety of medical cannabis prescribing.

Nitin Makadia
Director of Clinical Service Development, The Digital Health Assurance Company
Regulatory reform opens doors, but robust clinical governance, safety standards, and practical operational models are what turn policies into safe, sustainable patient care.
Read bio
Nitin Makadia is a GPhC-registered pharmacist, Clinical Safety Officer, and Director at The Digital Health Assurance Company with 35 years of experience across clinical pharmacy, digital health, and healthcare operations.
A specialist in the UK medical cannabis sector, Nitin advises clinics and health tech organisations on clinical service design, operational delivery and CQC regulatory readiness. His work bridges the gap between complex regulatory frameworks and practical, patient-centred care, ensuring innovative services scale safely and compliantly.
Speaking on European prescribing frameworks at the Cannabis Health Symposium, Nitin brings deep, practical insights into how UK prescribing models operate in practice, the regulatory and operational realities facing clinicians and dispensaries, and how cross-border governance standards can support responsible European medical cannabis expansion.

Dr Callie Seaman
Managing Director, Sunnyside Consultants
Across the world, cannabis policy has evolved in many different ways, yet patient self-sufficiency remains largely absent from the conversation. In the UK, patients still have no legal right to cultivate their own medicine. I want to challenge us to look beyond the cost of cannabis itself and explore the wider economic implications of patient self-sufficiency — not only for patients, but for our healthcare system, public finances and the taxpayer.
Read bio
Dr. Callie Seaman is a PhD plant scientist, formulation chemist, managing director of Sunnyside consultancy and Co-Founding Director of Aqua Laboratories, the manufacturers behind Shogun Fertilisers. With over 25 years of experience spanning hydroponics, large-scale cultivation, product formulation, and regulatory development, she brings both scientific depth and commercial expertise to everything she does.
Callie has worked internationally with cultivation facilities and was a director of one of the first licensed cannabis cultivation sites in the UK. As former Co-Chair of the Cannabis Industry Council and a trustee of the MedCan Family Foundation, she has helped shape policy, standards, and patient advocacy at the highest levels.
Having operated in both the legacy and regulated markets, she offers a rare 360-degree perspective on where this industry has come from — and where it’s going next.

Panos Papatheologou
Co-Founder & CEO, ReliefTime
Europe’s medical cannabis markets are developing at different speeds, and each one is a live experiment in what works for patients and physicians. We are looking forward to discussing what the German market can learn from them: access models, clinical standards and patient trust.
Read bio
Panos Papatheologou is Co-Founder and CEO of ReliefTime, Greece’s first and leading telemedicine platform specialising in medical cannabis and improving patient access through innovative digital healthcare solutions.
Inspired by international market developments, he co-founded ReliefTime to bridge the gap between patients and specialised physicians.
Since launching in 2025, ReliefTime has rapidly emerged as a key player in Greece’s evolving telemedicine and medical cannabis market, helping reshape how patients access specialised medical care.

David Tang
CEO & Founder, CannPrescribe
Read bio
Dr David Tang FRCEM PgDip(SEM) MBBS BSc is a UK physician whose clinical background spans emergency medicine and sport and exercise medicine. He has prescribed cannabis-based medicinal products (CBMPs) for five years, three of them at medical director level.
David is Chief Executive Officer of CannPrescribe, a UK initiative dedicated to raising prescribing standards and training the next generation of CBMP clinicians. Its CPD-accredited course prepares doctors to enter this developing field safely, competently and with appropriate governance, and this year alone CannPrescribe has brought ten new prescribers into CBMP practice.
He sits on the Expert Panel of the UK Medical Cannabis Clinicians Society (UKMCCS). His work centres on one aim: making CBMP prescribing in the UK consistent, defensible, transparent and anchored to meaningful patient outcomes, so that patients, policymakers and the wider profession can have confidence in a specialty that is still establishing its place within mainstream medicine.

Liam O'Dowd
Editor & Co-Founder, leafie
As the medical cannabis industry continues to grow, clinicians, prescribers and other professionals must listen carefully to the lived experiences of patients. Understanding how cannabis helps and where room for improvement lies can help build trust, bridging the gap between the industry and those who need cannabis the most. I'm delighted to host the patient panel, and I hope to see as many people from the industry there as possible.
Read bio
Liam is the editor and co-founder of leafie, a UK-based independent media platform launched in 2019. leafie explores cannabis and psychedelics from the perspective of patients and consumers, publishing both online and in print.
Launched shortly after the legalisation of medical cannabis in the UK, leafie has a unique perspective, acting as a conduit between patients and the industry.

Dr Iain Pryde
Consultant Psychiatrist, Tilray Medical x Lyphe Clinic
I look forward to an interesting discussion and learning from the other participants.
Read bio
Dr Pryde is a consultant psychiatrist with Lyphe Clinic. He joined the medical cannabis field in 2022, curious about the potential to address unmet needs where conventional treatments fall short. Recognising the gaps in our knowledge and the importance of balanced discourse regarding the risks and benefits of cannabis therapy, he tries to adopt an individualised approach to treatment, collaborating with patients to navigate decisions responsibly.
His many years of psychiatric experience include previous NHS consultant roles in an inner-city Assertive Outreach Service and sector community team, involving inpatient and community care of people with a wide range of mental health conditions including severe and complex mental illness.
He studied medicine at the University of Edinburgh, graduating with Honours and the class prize in psychiatry. He is a member of the Royal College of Psychiatrists and has a Master’s degree in Philosophy of Mental Disorder from King’s College London.

Adam Windish
CEO, British Cannabis; Education, Awareness & Standards Pillar Lead, Cannabis Industry Council
Nurses have a vital role to play in the future of medical cannabis care. Through this paper, the Cannabis Industry Council aims to raise awareness, support greater clinical understanding and encourage more informed, confident conversations between healthcare professionals and patients. I'm delighted to be presenting this work at the Cannabis Health Symposium in London this year.
Read bio
Adam Windish is CEO of BRITISH CANNABIS™, one of the UK’s leading cannabinoid companies, where he leads strategy, revenue, and the expansion of both medical and over the counter product lines.
He has played a key role in scaling distribution, building white label partnerships, and bringing new cannabinoid products to market across the UK and international markets. His work sits at the intersection of regulation, product development, and patient access, with a focus on building commercially viable pathways in a highly regulated environment.
Alongside his commercial role, Adam serves as the Cannabis Industry Council’s pillar lead for education, awareness, and standards, contributing to the development of clearer frameworks and guidance across the sector.
He regularly speaks on market development, regulation, and the future of medical cannabis in the UK and internationally.

Adam Cole
Chief Technology & Program Strategist, Goji Technology Systems Inc
Read bio
Adam is a healthtech executive with four successful exits, two to public companies, and 25+ years of leadership experience across clinical trials, patient support programs, and market access in regulated healthcare. His career spans some of the most operationally complex environments in health IT, including McKesson, Canadian Clinical Trial Network, Liberate Health, and Newtopia. He has developed and led clinical trials and patient support programs that required the same evidence rigour, compliance infrastructure, and stakeholder coordination that gojitech's platform is built to deliver at scale. Among many awards, Adam is particularly proud to have had a product inducted into the Smithsonian, been voted by his peers as Canadian IT Professional of the year, and overseen the development of the Canadian artificial pancreas.

Nabila Chaudhri
Medical Director, Montu UK / Alternaleaf
Read bio
Nabila Chaudhri, Medical Director at Alternaleaf and Montu's UK pharmacy, is a pharmacist and healthcare leader with over 15 years of experience. She has made significant contributions in clinical leadership and innovation in the field of medical cannabis as well as setting a new care standard for patients. Nabila has also led efforts in regulatory compliance, service development, and digital health. She holds an MPharm from King's College London and a Practice Certificate in Independent Prescribing. She has been recognised as a 'Woman to Watch' by the Royal Pharmaceutical Society and received the 'Excellence in Clinical Leadership' award.

Kate Thorpe
Executive Director, Medical Cannabis Clinicians Society (MCCS)
Medical cannabis and mental health is an area where honest, informed discussion really matters. I’m looking forward to exploring how we balance clinical freedom and expertise with the evidence and safeguards needed in mental health care - giving clinicians room to exercise their judgement while keeping patient safety at the centre.
Read bio
Kate Thorpe is Executive Director of the Medical Cannabis Clinicians Society (MCCS), where she leads strategy, governance, education and development. Part of the Society since its inception, she works closely with its committee to support clinicians, advance medical cannabis education and strengthen standards in safe, evidence-based prescribing.
Kate brings nearly 20 years of experience in healthcare communications, partnerships and strategic development, with a career centred on working alongside clinicians to develop specialist services and improve professional understanding. Her background spans NHS communications and senior roles in specialist neurological rehabilitation.
She is also Co-Founder and Director of Resilience Neuro Specialists, a specialist outpatient brain injury rehabilitation service.
Kate is committed to improving understanding of medical cannabis and its responsible use in clinical practice. Her focus is on practical education, informed prescribing and ensuring MCCS provides a clear, credible and influential voice for clinicians working with cannabis-based medicines.

Dr Zack Bellman
Lead Researcher, CRDG UK; Founder, Cannabinoid Pipeline Insights
Pharmaceutical cannabinoid R&D is expanding how we understand medicine, from the fundamental science of the endocannabinoid system through to the clinic. As global laws and the landscape around medical cannabis and cannabinoids change, addressing addiction, psychiatry and mental health will become increasingly important.
Read bio
Dr Zachary Bellman is a researcher and science writer based in London specialising in cannabinoid R&D, pharmacology and drug discovery. He holds a PhD in Pharmaceutical Sciences and an MRes in Drug Sciences from the UCL School of Pharmacy, alongside a BSc in Neuroscience from the University of Sussex. He is currently lead researcher at the Cannabinoid Research and Development Group (CRDG UK), supporting UK pharmaceutical research strategy, and recently founded Cannabinoid Pipeline Insights, providing independent analysis and news about pharmaceutical cannabinoid companies, clinical trials and R&D.

Nicola Stevenson
Prescribed patient, advocate & industry consultant, The M-C Fairy
I am honoured to sit on such an incredible panel, and hope to bring the voices and lived experiences of patients into deeper conversations around medical cannabis, its integration into healthcare, and wider reform.
Read bio
Nicola Stevenson is a prescribed medical cannabis patient and advocate who has used cannabis to treat a multitude of conditions and symptoms for the majority of her life. Since becoming a legal patient she has been able to taper off a number of medications, including strong opioids, and continues to use her prescription to manage her symptoms, conditions and the side effects of other pharmaceuticals.
As a patient she has consulted and worked with a number of charities, organisations and events to help improve access to fundamental information, as well as quality of life for patients within the community. She believes the biggest issues patients face are a lack of education and the lack of integration of medical cannabis into existing healthcare plans — something events like this are pivotal in changing.

Carola Pérez
Director, We, The Patients
Read bio
Carola Pérez is a patient advocate, international speaker, and We, The Patients director, an initiative built by and for patients to advance accessible, evidence-based education on medical cannabis and chronic conditions.
Founder of Dosemociones — the first patient association in Spain to campaign for medical cannabis legislation — and of the Spanish Observatory for Medical Cannabis, she has spent years embedding patient voices into national and European policy.
Her work is rooted in lived experience with severe neuropathic pain, taking her from testifying before the Spanish Parliament to contributing to the Manifesto for Global Access to Cannabinoid Therapies, published in Forbes to coincide with the UN Commission on Narcotic Drugs session in Vienna.
One clear purpose: that no patient feels unheard or without access to safe and effective treatment.

Julie Durrans
Prescribed patient & patient advocate
I’m looking forward to bringing a patient perspective to the discussion, sharing experiences and helping ensure that the voices of patients remain central to the future of medical cannabis.
Read bio
Julie Durrans is a UK prescribed medical cannabis patient of six years and a passionate patient advocate. Through her involvement in patient support groups and the wider cannabis community, she has supported and connected with many patients, sharing experiences and helping others navigate their own journeys with medical cannabis.
Drawing on both her personal experience and her connections with the patient community, Julie brings a lived-experience perspective to discussions around patient access, autonomy, affordability and the future of medical cannabis in the UK. She believes patients should have a meaningful voice in shaping the conversation around their treatment and the industry that serves them.
For Julie, medical cannabis has been about much more than symptom management. It has helped her reclaim aspects of life that chronic illness had taken away, including returning to her allotment, rediscovering her love of growing and finding a renewed sense of independence and purpose.

Sarah Sinclair
Editor, Cannabis Health
Call for speakers
Are you a clinician, researcher or specialist who’d like to present? We’re inviting speaker applications for the programme — tell us about your session.
Partners
Partner with us
Interested in sponsoring or partnering with the Cannabis Health Symposium? Register your interest and our team will be in touch about the opportunities.
Final Release£284.09incl. fees
HCP concession£100for healthcare professionals
Every ticket: CPD certified · 12 months' free MCCS membership, worth up to £120
Get symposium updates
A round-up of the latest science, regulation and developments across the UK and Europe — in your inbox every week.















